Open AccessSpecific metabolic biomarkers as risk and prognostic factors in colorectal cancer
Author(s) -
Małgorzata Muc-Wierzgoń,
Ewa Nowakowska-Zajdel,
Sylwia Dzięgielewska-Gęsiak,
Teresa Kokot,
Katarzyna Klakla,
Edyta Fatyga,
Elżbieta Grochowska-Niedworok,
Dariusz Waniczek,
Janusz Wierzgoń
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i29.9759
Subject(s) - hyperinsulinemia , colorectal cancer , adipokine , medicine , cancer , obesity , bioinformatics , glucose homeostasis , oncology , insulin resistance , epidemiology , carcinogenesis , biology
Advances in genomics, molecular pathology and metabolism have generated many candidate biomarkers of colorectal cancer with potential clinical value. Epidemiological and biological studies suggest a role for adiposity, dyslipidaemia, hyperinsulinemia, altered glucose homeostasis, and elevated expression of insulin-like growth factor (IGF) axis members in the risk and prognosis of cancer. This review discusses some recent past and current approaches being taken by researches in obesity and metabolic disorders. The authors describe three main systems as the most studied metabolic candidates of carcinogenesis: dyslipidemias, adipokines and insulin/IGF axis. However, each of these components is unsuccessful in defining the diseases risk and progression, while their co-occurrence increases cancer incidence and mortality in both men and women.